Hims & Hers shares tanked after regulators signaled new limits on the production of versions of weight-loss drugs.
EVgo stock surges after the company receives a $1 billion Energy Department loan commitment, Levi Strauss tumbles after ...
The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 ...
Anticipating a 35% CAGR in 2025, Hims & Hers is poised for substantial growth. Read why I maintain my strong buy rating on ...
Exploding sales of prescription weight loss medications have catapulted Novo Nordisk (NVO) and Eli Lilly (LLY) to become the ...
Eli Lilly (LLY)'s weight loss drugs Mounjaro and Zepbound are no longer facing supply constraints, as the FDA has removed ...
GET MORE AI-GENERATED SIGNALS: September 30, 2024, 17:16 pm ET, BY Rick O.- Contributor| Editor: Thomas H. Kee Jr. ( Follow ...
Hims & Hers is a fantastic value despite its high on-the-surface P/E ratio and valuation metrics. Click here to read why HIMS ...
Market-beating returns could be on the way for patient investors in these two up-and-coming healthcare growth stocks.
Hims & Hers (NASDAQ: HIMS) stock has done well since the company went public a few years ago. It has soared by over 193% in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback